Summary: Prolonged-release tacrolimus (Envarsus®) is a new, once-daily, prolonged-release tacrolimus formulation utilizing MeltDose®, a drug delivery technology designed to enhance the bioavailability of drugs with low water solubility by creating a solid solution of the drug. The pharmacokinetic profiles of LCPT and results of randomized clinical trials in stable and de novo renal transplant recipients are discussed. Preliminary efficacy data from phase II trials in de novo and stable, previously treated liver transplant recipients imply that tacrolimus LCPT is effective in these patient groups. Considering the studies conducted to date, once-daily LCP-Tacro has shown improved pharmacokinetic properties, rapid achievement of therapeutic trough levels, consistent exposure, non-inferior efficacy and similar safety, with a lower tacrolimus dose than other tacrolimus formulations. Tacrolimus LCPT is a promising addition to the treatment options available to kidney and liver transplant recipients.